Allergan Sues Sandoz Over Lumigan Patents

Law360, New York (August 29, 2011, 1:57 PM EDT) -- Drug giant Allergen Inc. sued a subsidiary of Swiss pharmaceutical company Novartis International AG on Friday in Texas federal court, alleging infringement of two patents for Lumigan, a topical medication used to treat glaucoma.

Allergen accused Sandoz Inc. of infringing U.S. Patent Numbers 7,851,504, titled “Enhanced bimatoprost ophthalmic solution,” and 5,688,819, titled “Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.”

The action came after Sandoz filed an abbreviated new drug application with the FDA, seeking approval to make and sell a 0.01 percent bimatoprost...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.